<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81182</article-id><article-id pub-id-type="doi">10.7554/eLife.81182</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-284727"><name><surname>Dagher</surname><given-names>Hiba</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-283327"><name><surname>Chaftari</surname><given-names>Anne-Marie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8097-8452</contrib-id><email>achaftari@mdanderson.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285516"><name><surname>Subbiah</surname><given-names>Ishwaria M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284731"><name><surname>Malek</surname><given-names>Alexandre E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284729"><name><surname>Jiang</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285517"><name><surname>Lamie</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285518"><name><surname>Granwehr</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285519"><name><surname>John</surname><given-names>Teny</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285520"><name><surname>Yepez</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284732"><name><surname>Borjan</surname><given-names>Jovan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285521"><name><surname>Reyes-Gibby</surname><given-names>Cielito</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4500-6476</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285522"><name><surname>Flores</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285523"><name><surname>Khawaja</surname><given-names>Fareed</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285524"><name><surname>Pande</surname><given-names>Mala</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285525"><name><surname>Ali</surname><given-names>Noman</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285526"><name><surname>Rojo</surname><given-names>Raniv</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285527"><name><surname>Karp</surname><given-names>Daniel D</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287432"><name><surname>Chaftari</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284730"><name><surname>Hachem</surname><given-names>Ray</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284734"><name><surname>Raad</surname><given-names>Issam I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Integrative Medicine Program, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Hospital Medicine, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Emergency Medicine-Research, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Gastroenterology Research, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Cancer Therapeutics, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>DaVita Labs</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>07</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81182</elocation-id><history><date date-type="received" iso-8601-date="2022-06-17"><day>17</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-23"><day>23</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-07-15"><day>15</day><month>07</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.13.22277579"/></event></pub-history><permissions><copyright-statement>© 2023, Dagher et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Dagher et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81182-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The long-term consequences of COVID-19 are not fully understood particularly in the cancer patient population. The purpose of this study is to assess post-acute sequelae of SARS-CoV-2 infection (PASC) in cancer patients following acute COVID-19 recovery.</p></sec><sec id="abs2"><title>Methods:</title><p>We identified cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-19 disease between March 1, 2020, and September 1, 2020, and followed them till May 2021. To assess PASC, we collected patients reported outcomes through questionnaires that were sent to patients daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. We also reviewed patients’ electronic medical records to capture the persistence or emergence of new COVID19-related symptoms reported during any clinic or hospital encounter beyond 30 days of the acute illness and up to 14 months.</p></sec><sec id="abs3"><title>Results:</title><p>We included 312 cancer patients with a median age of 57 years (18–86). The majority of patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis. The most common symptoms reported included fatigue (82%), sleep disturbances (78%), myalgias (67%), and gastrointestinal symptoms (61%), followed by headache, altered smell or taste, dyspnea (47%), and cough (46%). A higher number of females reported a persistence of symptoms compared to males (63% vs. 37%; p=0.036). Cancer type, neutropenia, lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in both groups. Among the 188 patients with PASC, only 16 (8.5%) were re-admitted for COVID-related reasons.</p></sec><sec id="abs4"><title>Conclusions:</title><p>More than one out of two cancer patients, and more likely females, report PASC that may persist beyond 6 months and even 1 year. The most common symptoms are non-respiratory and consist of fatigue, sleep disturbance, myalgia, and gastrointestinal symptoms. Most of the cancer patients with PASC were managed on outpatient basis with only 8.5% requiring a COVID-19-related re-admission.</p></sec><sec id="abs5"><title>Funding:</title><p>This research is supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer Center Clinical Trials Office. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer patients</kwd><kwd>immunocompromised</kwd><kwd>COVID-19</kwd><kwd>long COVID</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA016672</award-id><principal-award-recipient><name><surname>Dagher</surname><given-names>Hiba</given-names></name><name><surname>Chaftari</surname><given-names>Anne-Marie</given-names></name><name><surname>Subbiah</surname><given-names>Ishwaria M</given-names></name><name><surname>Malek</surname><given-names>Alexandre E</given-names></name><name><surname>Jiang</surname><given-names>Ying</given-names></name><name><surname>Lamie</surname><given-names>Peter</given-names></name><name><surname>Granwehr</surname><given-names>Bruno</given-names></name><name><surname>John</surname><given-names>Teny</given-names></name><name><surname>Yepez</surname><given-names>Eduardo</given-names></name><name><surname>Borjan</surname><given-names>Jovan</given-names></name><name><surname>Reyes-Gibby</surname><given-names>Cielito</given-names></name><name><surname>Flores</surname><given-names>Mary</given-names></name><name><surname>Khawaja</surname><given-names>Fareed</given-names></name><name><surname>Pande</surname><given-names>Mala</given-names></name><name><surname>Ali</surname><given-names>Noman</given-names></name><name><surname>Rojo</surname><given-names>Raniv</given-names></name><name><surname>Karp</surname><given-names>Daniel D</given-names></name><name><surname>Hachem</surname><given-names>Ray</given-names></name><name><surname>Raad</surname><given-names>Issam I</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Long COVID occurred in the majority of cancer patients diagnosed with acute COVID-19 with a preponderance of symptoms (such as fatigue, sleep disturbances, and gastrointestinal symptoms) over a long time period.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Clinical outcomes of COVID-19 in patients with cancer remains an area of active study with several studies showing more severe outcomes and associated risk factors such as pre-existing comorbidities, cancer stage and therapy, and immunocompromised state, compared to the non-cancer population (<xref ref-type="bibr" rid="bib5">Dai et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Petrilli et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Wu and McGoogan, 2020</xref>; <xref ref-type="bibr" rid="bib23">Zhou et al., 2020</xref>).</p><p>The earliest studies characterized the acute and sub-acute effects of COVID-19 on multiple organ systems (<xref ref-type="bibr" rid="bib9">Gupta et al., 2020</xref>) while more recent work has raised concern on the chronic symptoms attributed to COVID-19 that persist beyond the expected recovery period (<xref ref-type="bibr" rid="bib2">Barman et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>) with some symptoms similar to those experienced during the recovery of other viral illnesses (<xref ref-type="bibr" rid="bib22">Xiong et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Ahmed et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Hui et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Kausler et al., 1986</xref>; <xref ref-type="bibr" rid="bib15">Moldofsky and Patcai, 2011</xref>).</p><p>The long-term consequences of COVID-19 remain to be fully understood and there is no unequivocal consensus on the definition of post-acute sequelae of SARS-CoV-2 infection (PASC), with one adopted definition being the persistence of symptoms or new delayed complications that develop at least 4 weeks after a COVID-19 diagnosis (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Datta et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Greenhalgh et al., 2020</xref>). The reported prevalence of PASC widely varies from 10% up to 87% in the general population (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Xiong et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Bowles et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Carfì et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Halpin et al., 2021</xref>) and there is limited data available on PASC in cancer patients and how it affects their cancer progression, care, and treatment.</p><p>Several studies suggest the persistence of symptoms past 30 days in patients with severe initial COVID-19 symptoms and those that were hospitalized due to COVID-19 (<xref ref-type="bibr" rid="bib2">Barman et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Carfì et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Halpin et al., 2021</xref>), while other studies have shown a prevalence of PASC among COVID-19 outpatients as well (<xref ref-type="bibr" rid="bib22">Xiong et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Tenforde et al., 2020b</xref>). Since cancer patients fall in a higher COVID-19 risk group (<xref ref-type="bibr" rid="bib5">Dai et al., 2020</xref>) and in order to provide a better understanding of post-COVID-19 management among cancer patients, we sought to characterize the patterns of long COVID-19 in the specific cancer patient population.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><p>We identified patients with cancer receiving care at the University of Texas MD Anderson Cancer Center who were also diagnosed with COVID-19 disease between March 1, 2020, and September 1, 2020. None of the patients were vaccinated during the period of initial COVID diagnosis. We followed these patients as longitudinal cohort through patient-reported outcomes (PRO)-based remote symptom monitoring along with usual care with clinician visits. Patients were followed from March 2020 until May 31, 2021. Patient questionnaires were sent out remotely daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. Chart reviews were conducted for each patient’s encounter that included visits to our acute cancer care center, hospital re-admission, or clinic visit. Re-admissions were classified as either related or non-related to COVID-19 based on the reason for hospitalization as well as the reported signs and symptoms. PASC or long COVID-19 was defined as the persistence of COVID-19-related symptoms beyond 30 days of diagnosis or the emergence of new COVID19-related symptoms reported during a hospital or clinic encounter throughout the follow-up period that extended up to 14 months. COVID-19-related symptoms included, among others, fatigue, cough, chest tightness, dyspnea, headache, fever, altered smell or taste, myalgias, gastrointestinal symptoms (such as nausea, vomiting, or diarrhea), sleep disturbance, and limitations with activities of daily living. This study was approved by the institutional review board at MD Anderson. A waiver of informed consent was obtained since this study posed no risk to the patients given that no clinical or laboratory interventions were done.</p><sec id="s2-1"><title>Statistical analysis</title><p>Categorical variables were compared using chi-square or Fisher’s exact test, as appropriate. Continuous variables were compared using Wilcoxon rank sum test. All the tests were two-sided with a significance level of 0.05. The statistical analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>Among the 602 patients who were diagnosed with COVID-19 during the study period, longitudinal data was collected on 312 patients that included 188 patients who developed PASC having reported symptoms that persisted at least 30 days after COVID-19 diagnosis and 124 who did not. The remaining patients (290) could not be followed or assessed beyond 30 days. The female gender rate was significantly higher in the PASC group compared to the non-PASC group (63% vs. 51%; p=0.036). The age and race were similar in both groups. The median age was 57, and 27% of both groups were above 65 years of age. While the rate of hypertension was higher in the non-PASC group (56% vs. 37%; p&lt;0.001), the rate of other comorbidities such as COPD and congestive heart failures were similar in both groups. Furthermore, the type of underlying cancer was similar in both groups with the majority of patients having solid tumors. The type of underlying malignancy (hematological vs. solid tumor) as well as those with metastatic diseases were similar in both PASC and non-PASC groups. However, patients with PASC were significantly less likely to have refractory or relapse diseases (19% vs. 29%) In addition, the rate of neutropenia, lymphocytopenia, lower respiratory tract infections, hypoxia, oxygen requirement, inflammatory biomarkers, COVID-19-related hospital admissions, multiorgan failure as well as medical management of COVID-19 were similar in both groups (<xref ref-type="table" rid="table1">Table 1</xref>). Despite that, the rates of delay in cancer treatment after COVID were similar in both PASC and non-PASC patients (43% vs. 38%; p=0.44). Patients without PASC were more likely to have more acute severe COVID at diagnosis than patients who developed PASC (26% vs. 14%; p=0.009) and had a higher mortality beyond 30 days of initial COVID diagnosis (27% vs. 10%; p&lt;0.0001). The 312 patients who were assessed beyond 30 days were followed for a median duration of 7 months and up to 14 months.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Comparing COVID-19 cancer patients with and without long-term symptoms (at least 30 days after their COVID-19 diagnosis).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variables</th><th align="left" valign="bottom">Having long-term symptoms</th><th align="left" valign="bottom"/><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">(n=124)</td><td align="left" valign="bottom">(n=188)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">N (%)</td><td align="left" valign="bottom">N (%)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Age (years), median (range)</td><td align="left" valign="bottom">57 (18–85)</td><td align="left" valign="bottom">57 (21–86)</td><td align="left" valign="bottom">0.47</td></tr><tr><td align="left" valign="bottom">Age ≥65</td><td align="left" valign="bottom">33 (27)</td><td align="left" valign="bottom">50 (27)</td><td align="left" valign="bottom">&gt;0.99</td></tr><tr><td align="left" valign="bottom">Gender</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.036</td></tr><tr><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">61 (49)</td><td align="left" valign="bottom">70 (37)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">63 (51)</td><td align="left" valign="bottom">118 (63)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Race</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.45</td></tr><tr><td align="left" valign="bottom">Caucasian</td><td align="left" valign="bottom">66 (53)</td><td align="left" valign="bottom">102 (54)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Black</td><td align="left" valign="bottom">24 (19)</td><td align="left" valign="bottom">26 (14)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Hispanic</td><td align="left" valign="bottom">28 (23)</td><td align="left" valign="bottom">52 (28)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Asian</td><td align="left" valign="bottom">5 (4)</td><td align="left" valign="bottom">8 (4)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">1 (1)</td><td align="left" valign="bottom">0 (0)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Prior COPD/bronchiolitis obliterans</td><td align="left" valign="bottom">4 (3)</td><td align="left" valign="bottom">7 (4)</td><td align="left" valign="bottom">&gt;0.99</td></tr><tr><td align="left" valign="bottom">History of hypertension</td><td align="left" valign="bottom">70 (56)</td><td align="left" valign="bottom">69/187 (37)</td><td align="left" valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">History of heart failure</td><td align="left" valign="bottom">3 (2)</td><td align="left" valign="bottom">5/186 (3)</td><td align="left" valign="bottom">&gt;0.99</td></tr><tr><td align="left" valign="bottom">Type of cancer</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.92</td></tr><tr><td align="left" valign="bottom">Hematological malignancy</td><td align="left" valign="bottom">31 (25)</td><td align="left" valign="bottom">48 (26)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Solid tumor</td><td align="left" valign="bottom">93 (75)</td><td align="left" valign="bottom">140 (74)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Metastasis</td><td align="left" valign="bottom">42/93 (45)</td><td align="left" valign="bottom">74/140 (53)</td><td align="left" valign="bottom">0.25</td></tr><tr><td align="left" valign="bottom">Status of cancer</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.023</td></tr><tr><td align="left" valign="bottom">Being treated initially</td><td align="left" valign="bottom">65/123 (53)</td><td align="left" valign="bottom">96 (51)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Remission</td><td align="left" valign="bottom">22/123 (18)</td><td align="left" valign="bottom">56 (30)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Refractory or relapse</td><td align="left" valign="bottom">36/123 (29)</td><td align="left" valign="bottom">36 (19)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemotherapy within 1 year prior to COVID-19</td><td align="left" valign="bottom">74 (60)</td><td align="left" valign="bottom">94 (50)</td><td align="left" valign="bottom">0.09</td></tr><tr><td align="left" valign="bottom">Immunotherapy within 6 months prior to COVID-19</td><td align="left" valign="bottom">7/123 (6)</td><td align="left" valign="bottom">9/186 (5)</td><td align="left" valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom">Radiation therapy within 6 months prior to COVID-19</td><td align="left" valign="bottom">12 (10)</td><td align="left" valign="bottom">20 (11)</td><td align="left" valign="bottom">0.78</td></tr><tr><td align="left" valign="bottom">Severe COVID-19 at diagnosis</td><td align="left" valign="bottom">32 (26)</td><td align="left" valign="bottom">25 (14)</td><td align="left" valign="bottom">0.009</td></tr><tr><td align="left" valign="bottom">Cancer treatment delayed</td><td align="left" valign="bottom">46/108 (43)</td><td align="left" valign="bottom">66/174 (38)</td><td align="left" valign="bottom">0.44</td></tr><tr><td align="left" valign="bottom">Mortality<xref ref-type="table-fn" rid="table1fn1">*</xref></td><td align="left" valign="bottom">33 (27)</td><td align="left" valign="bottom">18 (10)</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Hypoxia at diagnosis</td><td align="left" valign="bottom">25 (20)</td><td align="left" valign="bottom">23/180 (13)</td><td align="left" valign="bottom">0.08</td></tr><tr><td align="left" valign="bottom">Oxygen flow at diagnosis</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.20</td></tr><tr><td align="left" valign="bottom">High flow</td><td align="left" valign="bottom">6/30 (20)</td><td align="left" valign="bottom">6/43 (14)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Low flow</td><td align="left" valign="bottom">15/30 (50)</td><td align="left" valign="bottom">15/43 (35)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">None</td><td align="left" valign="bottom">9/30 (30)</td><td align="left" valign="bottom">22/43 (51)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Non-invasive ventilation at diagnosis</td><td align="left" valign="bottom">16 (13)</td><td align="left" valign="bottom">13/179 (7)</td><td align="left" valign="bottom">0.10</td></tr><tr><td align="left" valign="bottom">Lab values at COVID-19 diagnosis</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">ALC &lt;1 K/µL</td><td align="left" valign="bottom">44/74 (59)</td><td align="left" valign="bottom">57/94 (61)</td><td align="left" valign="bottom">0.88</td></tr><tr><td align="left" valign="bottom">ANC &lt;0.5 K/µL</td><td align="left" valign="bottom">5/75 (7)</td><td align="left" valign="bottom">5/89 (6)</td><td align="left" valign="bottom">&gt;0.99</td></tr><tr><td align="left" valign="bottom">Hemoglobin &lt;10 g/dL</td><td align="left" valign="bottom">23/65 (35)</td><td align="left" valign="bottom">16/78 (21)</td><td align="left" valign="bottom">0.06</td></tr><tr><td align="left" valign="bottom">LDH ≥250 U/L</td><td align="left" valign="bottom">29/58 (50)</td><td align="left" valign="bottom">41/67 (61)</td><td align="left" valign="bottom">0.21</td></tr><tr><td align="left" valign="bottom">D-dimer ≥1 mcg/mL</td><td align="left" valign="bottom">28/54 (52)</td><td align="left" valign="bottom">27/61 (44)</td><td align="left" valign="bottom">0.42</td></tr><tr><td align="left" valign="bottom">Ferritin ≥500 ng/mL</td><td align="left" valign="bottom">30/54 (56)</td><td align="left" valign="bottom">36/59 (61)</td><td align="left" valign="bottom">0.56</td></tr><tr><td align="left" valign="bottom">CRP ≥40 mg/L</td><td align="left" valign="bottom">32/56 (57)</td><td align="left" valign="bottom">43/63 (68)</td><td align="left" valign="bottom">0.21</td></tr><tr><td align="left" valign="bottom">IL-6 ≥25 pg/mL</td><td align="left" valign="bottom">18/41 (44)</td><td align="left" valign="bottom">20/48 (42)</td><td align="left" valign="bottom">0.83</td></tr><tr><td align="left" valign="bottom">LRTI at diagnosis or progression to LRTI</td><td align="left" valign="bottom">29 (23)</td><td align="left" valign="bottom">35/182 (19)</td><td align="left" valign="bottom">0.38</td></tr><tr><td align="left" valign="bottom">Hospital admission</td><td align="left" valign="bottom">52 (42)</td><td align="left" valign="bottom">65 (35)</td><td align="left" valign="bottom">0.19</td></tr><tr><td align="left" valign="bottom">Remdesivir treatment</td><td align="left" valign="bottom">17 (14)</td><td align="left" valign="bottom">18 (10)</td><td align="left" valign="bottom">0.26</td></tr><tr><td align="left" valign="bottom">IL-6 pathway inhibitors – tocilizumab</td><td align="left" valign="bottom">8 (6)</td><td align="left" valign="bottom">5 (3)</td><td align="left" valign="bottom">0.10</td></tr><tr><td align="left" valign="bottom">Convalescent plasma</td><td align="left" valign="bottom">8 (6)</td><td align="left" valign="bottom">15 (8)</td><td align="left" valign="bottom">0.61</td></tr><tr><td align="left" valign="bottom">Steroids</td><td align="left" valign="bottom">18 (15)</td><td align="left" valign="bottom">19 (10)</td><td align="left" valign="bottom">0.24</td></tr><tr><td align="left" valign="bottom">Multiorgan failure</td><td align="left" valign="bottom">6/121 (5)</td><td align="left" valign="bottom">8/180 (4)</td><td align="left" valign="bottom">0.84</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>1. Patients who died within 30 days after COVID-19 diagnosis were excluded from this study. 2. Mortality status was determined within 14 months after COVID-19 diagnosis.</p></fn></table-wrap-foot></table-wrap><p>The most commonly reported symptoms among the 188 patients who developed PASC consisted of fatigue (82%), sleep disturbance (78%), myalgias (67%), gastrointestinal symptoms (62%), headache (47%), altered smell and taste (47%), dyspnea (47%), and cough (46%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Post-acute sequela of SARS-CoV-2 infection (PASC)-related symptoms.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81182-fig1-v2.tif"/></fig><p>Among the 188 cancer patients who reported PASC, 59 patients (31%) were re-admitted to the hospital during the follow-up period and beyond 30 days of acute illness, only 16 (8.5%) of the patients with PASC had a COVID-related re-admission.</p></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Our data showed that 60% of 312 cancer patients diagnosed with COVID and followed up for a median duration of 7 month (up to 14 month) developed PASC. Females were more likely to report persistence of symptoms compared to males. However, cancer type, age, neutropenia, lymphocytopenia, hypoxia, severe disease, multiorgan failure, various interventions, or hospital admission during acute COVID-19 disease were not associated with higher risk of long COVID in our study group, while hypertension was more significantly associated with no PASC during follow-up. Furthermore, high-risk patients with baseline relapsing and refractory malignancy were associated with more acute severe COVID and higher mortality but less long-term COVID. The most common PASC symptoms were fatigue, sleep disturbances, myalgias, and gastrointestinal symptoms. Furthermore, among PASC patients who were re-hospitalized for any cause during the follow-up, the admission was COVID-related in only 27%.</p><p>In a manner similar to our current study, the CDC reported that 60% of patients with immunosuppressive conditions continue to have COVID-19 symptoms beyond the acute illness (<xref ref-type="bibr" rid="bib19">Tenforde et al., 2020b</xref>). In the same CDC study, hypertension was found to be significantly less often associated with PASC which is another similar finding noted in our study. It is unknown from a pathophysiologic perspective as to why hypertension, which is a risk factor for acute and severe COVID-19, should be less associated with PASC. However given the fact that the pathogenesis of acute COVID-19 is related to the interaction of the viral spike protein with the angiotensin-converting enzyme 2 (ACE 2), one could postulate that this pathway does not play an important role in long COVID compared to the residual inflammatory processes that seem to continue to occur in PASC (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Kaseb et al., 2021</xref>). Similarly, males are at greater risk of acute complications and death associated with acute COVID-19 possibly related to higher ACE 2 expression levels in the male gender (<xref ref-type="bibr" rid="bib13">Kaseb et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Jin et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Viveiros et al., 2021</xref>). However, in our study females were more likely to develop PASC also suggesting a different mechanism of action for PASC besides ACE 2 expression (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>).</p><p>The existing literature has also shown a higher prevalence of PASC and a longer time to recovery among those with more severe COVID-19 who required hospital admission and medical interventions (<xref ref-type="bibr" rid="bib2">Barman et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Carfì et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Halpin et al., 2021</xref>). However, there has been several reports of PASC among patients with self-reported COVID-19 who had mild acute illness and were never hospitalized (<xref ref-type="bibr" rid="bib22">Xiong et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Tenforde et al., 2020b</xref>; <xref ref-type="bibr" rid="bib18">Tenforde et al., 2020a</xref>). In our study, severe acute COVID associated with hypoxia, multiorgan failure, hospital admission, or underlying risk factors for the progression of acute COVID-19 in cancer patients such as neutropenia, lymphocytopenia, hematologic malignancy, or older age were not associated with increased risk of long COVID.</p><p>In the general population and following acute COVID-19, PASC symptoms occurred at a variable rate ranging from 10% to 87% (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Xiong et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Bowles et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Carfì et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Halpin et al., 2021</xref>). In a manner similar to our results, fatigue was the most prevalent PASC symptom in many reports occurring in up to 87% of COVID-19 patients compared to 82% in our patient population (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Carfì et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Halpin et al., 2021</xref>). Other common PASC symptoms reported in our study such as sleep disturbances, myalgias, gastrointestinal symptoms, headache, loss of smell and taste, dyspnea, and cough were also widely and commonly reported in the COVID-19 literature (<xref ref-type="bibr" rid="bib16">Nalbandian et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Xiong et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Goërtz et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Bowles et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Carfì et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Halpin et al., 2021</xref>). However, all of these symptoms commonly occur in patients with underlying malignancy who continue to receive treatment with conventional chemotherapy, radiotherapy, and immunotherapy (including checkpoint inhibitors). Hence, the rates of some of these PASC symptoms in the cancer patient population could be exaggerated and partially related to the underlying malignancy and its treatment.</p><p>In our cancer patient population, PASC was not associated with a high rate of COVID 19-related hospital admissions during the follow-up. All cause admissions occurred at a rate of 31% among our cancer patients with PASC and among those who were admitted only 27% were admitted because of COVID-19-related reasons. Hence, among all PASC patients in our study only 8.5% were admitted for COVID 19-related reasons. Furthermore, some of those few that were admitted for COVID-19-related reasons could have had reinfection with a new variant during the prolonged follow-up period or reactivation related to their immunosuppressed status. Hence, even in our high-risk cancer patient population, most of the symptoms associated with PASC were managed for the most part on an outpatient basis without the need for hospital admission.</p><p>Our study has its limitations. First, the retrospective nature of this study limits any firm conclusions about factors directly contributing to PASC in our COVID-19 cancer patients. Second, this is a single center study which could also limit the generalization of our results. Third, the subjective nature of surveys in the absence of quality of life assessment scales and other verified objective scales to assess reported PASC criteria could also limit our conclusions. Finally, the presence of several confounding causes of hospital admissions and overlapping symptoms in cancer patients that may be due to their underlying disease, aggressive treatments, and comorbidities present their own challenge in identifying PASC among cancer patients post their COVID-19 diagnosis.</p><p>In conclusion, long COVID occurred in the majority of our cancer patients diagnosed with acute COVID-19 with a preponderance of symptoms (such as fatigue, sleep disturbances, and gastrointestinal symptoms) over a long time period. Long COVID was less likely in patients who experienced severe acute COVID at diagnosis and who had a higher mortality rate. Most of the patients with long COVID/PASC were fairly and adequately managed on outpatient basis without the need for hospital admission. Besides the female gender, we found no other underlying condition or severity of illness during acute COVID-19 that would predict PASC.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Writing - original draft, Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Writing - review and editing, oversight and leadership responsibilities, including mentorship interpretation of data</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Writing - original draft, Writing - review and editing, interpretation of data</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Writing - original draft, Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con5"><p>Data curation, Software, Formal analysis, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Visualization, Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con7"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con8"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con9"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con10"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con11"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con12"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con13"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con14"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con15"><p>critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con16"><p>Writing - review and editing, critical review, commentary acquisition of data</p></fn><fn fn-type="con" id="con17"><p>Writing - review and editing, critical review, commentary</p></fn><fn fn-type="con" id="con18"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Writing - original draft, Writing - review and editing, interpretation of data critical review, commentary oversight and leadership responsibilities, including mentorship</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Writing - original draft, Writing - review and editing, Interpretation of Data oversight and leadership responsibilities, including mentorship</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study was approved by the institutional review board at MD Anderson. A waiver of informed consent was obtained since this study posed no risk to the patients given that no clinical or laboratory interventions were done.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81182-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data Availability Statement: The study protocol, statistical analysis plan, lists of deidentified individual data, generated tables and figures will be made available upon request by qualified scientific and medical researchers for legitimate research purposes. Requests should be sent to <ext-link ext-link-type="uri" xlink:href="https://faculty.mdanderson.org/profiles/anne-marie_chaftari.html">https://faculty.mdanderson.org/profiles/anne-marie_chaftari.html</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.linkedin.com/in/yjiang2008">yijiang@mdanderson.org</ext-link>. Data will be available on request for 6 months from the date of publication. Investigators are invited to submit study proposal requests detailing research questions and hypotheses in order to receive access to these data.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Ms Salli Saxton, Department of Infectious Diseases, Infection Control and Employee Health, MD Anderson Cancer Center, Houston, for helping with the submission of the manuscript. This research was supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672, which supports MD Anderson Cancer Center’s Clinical Trials Office.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Greenwood</surname><given-names>DC</given-names></name><name><surname>Halpin</surname><given-names>S</given-names></name><name><surname>Lewthwaite</surname><given-names>P</given-names></name><name><surname>Salawu</surname><given-names>A</given-names></name><name><surname>Eyre</surname><given-names>L</given-names></name><name><surname>Breen</surname><given-names>A</given-names></name><name><surname>O’Connor</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Sivan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Long-Term clinical outcomes in survivors of severe acute respiratory syndrome and middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis</article-title><source>Journal of Rehabilitation Medicine</source><volume>52</volume><elocation-id>jrm00063</elocation-id><pub-id pub-id-type="doi">10.2340/16501977-2694</pub-id><pub-id pub-id-type="pmid">32449782</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barman</surname><given-names>MP</given-names></name><name><surname>Rahman</surname><given-names>T</given-names></name><name><surname>Bora</surname><given-names>K</given-names></name><name><surname>Borgohain</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 pandemic and its recovery time of patients in India: a pilot study</article-title><source>Diabetes &amp; Metabolic Syndrome</source><volume>14</volume><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.07.004</pub-id><pub-id pub-id-type="pmid">32673841</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowles</surname><given-names>KH</given-names></name><name><surname>McDonald</surname><given-names>M</given-names></name><name><surname>Barrón</surname><given-names>Y</given-names></name><name><surname>Kennedy</surname><given-names>E</given-names></name><name><surname>O’Connor</surname><given-names>M</given-names></name><name><surname>Mikkelsen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Surviving COVID-19 after hospital discharge: symptom, functional, and adverse outcomes of home health recipients</article-title><source>Annals of Internal Medicine</source><volume>174</volume><fpage>316</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.7326/M20-5206</pub-id><pub-id pub-id-type="pmid">33226861</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carfì</surname><given-names>A</given-names></name><name><surname>Bernabei</surname><given-names>R</given-names></name><name><surname>Landi</surname><given-names>F</given-names></name><collab>Gemelli Against COVID-19 Post-Acute Care Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Persistent symptoms in patients after acute COVID-19</article-title><source>JAMA</source><volume>324</volume><fpage>603</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.12603</pub-id><pub-id pub-id-type="pmid">32644129</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>S</given-names></name><name><surname>Zhen</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name><name><surname>Chai</surname><given-names>L</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Santillana</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Patients with cancer appear more vulnerable to SARS-cov-2: a multicenter study during the COVID-19 outbreak</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>783</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0422</pub-id><pub-id pub-id-type="pmid">32345594</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>SD</given-names></name><name><surname>Talwar</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A proposed framework and timeline of the spectrum of disease due to SARS-cov-2 infection: illness beyond acute infection and public health implications</article-title><source>JAMA</source><volume>324</volume><fpage>2251</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.22717</pub-id><pub-id pub-id-type="pmid">33206133</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goërtz</surname><given-names>YMJ</given-names></name><name><surname>Van Herck</surname><given-names>M</given-names></name><name><surname>Delbressine</surname><given-names>JM</given-names></name><name><surname>Vaes</surname><given-names>AW</given-names></name><name><surname>Meys</surname><given-names>R</given-names></name><name><surname>Machado</surname><given-names>FVC</given-names></name><name><surname>Houben-Wilke</surname><given-names>S</given-names></name><name><surname>Burtin</surname><given-names>C</given-names></name><name><surname>Posthuma</surname><given-names>R</given-names></name><name><surname>Franssen</surname><given-names>FME</given-names></name><name><surname>van Loon</surname><given-names>N</given-names></name><name><surname>Hajian</surname><given-names>B</given-names></name><name><surname>Spies</surname><given-names>Y</given-names></name><name><surname>Vijlbrief</surname><given-names>H</given-names></name><name><surname>van ’t Hul</surname><given-names>AJ</given-names></name><name><surname>Janssen</surname><given-names>DJA</given-names></name><name><surname>Spruit</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Persistent symptoms 3 months after a SARS-cov-2 infection: the post-COVID-19 syndrome?</article-title><source>ERJ Open Research</source><volume>6</volume><elocation-id>00542-2020</elocation-id><pub-id pub-id-type="doi">10.1183/23120541.00542-2020</pub-id><pub-id pub-id-type="pmid">33257910</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenhalgh</surname><given-names>T</given-names></name><name><surname>Knight</surname><given-names>M</given-names></name><name><surname>A’Court</surname><given-names>C</given-names></name><name><surname>Buxton</surname><given-names>M</given-names></name><name><surname>Husain</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Management of post-acute covid-19 in primary care</article-title><source>BMJ</source><volume>370</volume><elocation-id>m3026</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m3026</pub-id><pub-id pub-id-type="pmid">32784198</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Sehrawat</surname><given-names>TS</given-names></name><name><surname>Bikdeli</surname><given-names>B</given-names></name><name><surname>Ahluwalia</surname><given-names>N</given-names></name><name><surname>Ausiello</surname><given-names>JC</given-names></name><name><surname>Wan</surname><given-names>EY</given-names></name><name><surname>Freedberg</surname><given-names>DE</given-names></name><name><surname>Kirtane</surname><given-names>AJ</given-names></name><name><surname>Parikh</surname><given-names>SA</given-names></name><name><surname>Maurer</surname><given-names>MS</given-names></name><name><surname>Nordvig</surname><given-names>AS</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name><name><surname>Bathon</surname><given-names>JM</given-names></name><name><surname>Mohan</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>KA</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Uriel</surname><given-names>N</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Elkind</surname><given-names>MSV</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Bilezikian</surname><given-names>JP</given-names></name><name><surname>Landry</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Extrapulmonary manifestations of COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1017</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id><pub-id pub-id-type="pmid">32651579</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpin</surname><given-names>SJ</given-names></name><name><surname>McIvor</surname><given-names>C</given-names></name><name><surname>Whyatt</surname><given-names>G</given-names></name><name><surname>Adams</surname><given-names>A</given-names></name><name><surname>Harvey</surname><given-names>O</given-names></name><name><surname>McLean</surname><given-names>L</given-names></name><name><surname>Walshaw</surname><given-names>C</given-names></name><name><surname>Kemp</surname><given-names>S</given-names></name><name><surname>Corrado</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Collins</surname><given-names>T</given-names></name><name><surname>O’Connor</surname><given-names>RJ</given-names></name><name><surname>Sivan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation</article-title><source>Journal of Medical Virology</source><volume>93</volume><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1002/jmv.26368</pub-id><pub-id pub-id-type="pmid">32729939</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Joynt</surname><given-names>GM</given-names></name><name><surname>Wong</surname><given-names>KT</given-names></name><name><surname>Gomersall</surname><given-names>CD</given-names></name><name><surname>Li</surname><given-names>TS</given-names></name><name><surname>Antonio</surname><given-names>G</given-names></name><name><surname>Ko</surname><given-names>FW</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Chan</surname><given-names>DP</given-names></name><name><surname>Tong</surname><given-names>MW</given-names></name><name><surname>Rainer</surname><given-names>TH</given-names></name><name><surname>Ahuja</surname><given-names>AT</given-names></name><name><surname>Cockram</surname><given-names>CS</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors</article-title><source>Thorax</source><volume>60</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1136/thx.2004.030205</pub-id><pub-id pub-id-type="pmid">15860716</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>JM</given-names></name><name><surname>Bai</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>XF</given-names></name><name><surname>Han</surname><given-names>DM</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gender differences in patients with COVID-19: focus on severity and mortality</article-title><source>Frontiers in Public Health</source><volume>8</volume><elocation-id>152</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2020.00152</pub-id><pub-id pub-id-type="pmid">32411652</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaseb</surname><given-names>AO</given-names></name><name><surname>Mohamed</surname><given-names>YI</given-names></name><name><surname>Malek</surname><given-names>AE</given-names></name><name><surname>Raad</surname><given-names>II</given-names></name><name><surname>Altameemi</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Kaseb</surname><given-names>OA</given-names></name><name><surname>Kaseb</surname><given-names>SA</given-names></name><name><surname>Selim</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impact of angiotensin-converting enzyme 2 (ACE2) expression on the incidence and severity of COVID-19 infection</article-title><source>Pathogens</source><volume>10</volume><elocation-id>379</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10030379</pub-id><pub-id pub-id-type="pmid">33809851</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kausler</surname><given-names>DH</given-names></name><name><surname>Lichty</surname><given-names>W</given-names></name><name><surname>Hakami</surname><given-names>MK</given-names></name><name><surname>Freund</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Activity duration and adult age differences in memory for activity performance</article-title><source>Psychology and Aging</source><volume>1</volume><fpage>80</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1037//0882-7974.1.1.80</pub-id><pub-id pub-id-type="pmid">3267384</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldofsky</surname><given-names>H</given-names></name><name><surname>Patcai</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study</article-title><source>BMC Neurology</source><volume>11</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2377-11-37</pub-id><pub-id pub-id-type="pmid">21435231</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalbandian</surname><given-names>A</given-names></name><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>McGroder</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>JS</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Nordvig</surname><given-names>AS</given-names></name><name><surname>Shalev</surname><given-names>D</given-names></name><name><surname>Sehrawat</surname><given-names>TS</given-names></name><name><surname>Ahluwalia</surname><given-names>N</given-names></name><name><surname>Bikdeli</surname><given-names>B</given-names></name><name><surname>Dietz</surname><given-names>D</given-names></name><name><surname>Der-Nigoghossian</surname><given-names>C</given-names></name><name><surname>Liyanage-Don</surname><given-names>N</given-names></name><name><surname>Rosner</surname><given-names>GF</given-names></name><name><surname>Bernstein</surname><given-names>EJ</given-names></name><name><surname>Mohan</surname><given-names>S</given-names></name><name><surname>Beckley</surname><given-names>AA</given-names></name><name><surname>Seres</surname><given-names>DS</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Uriel</surname><given-names>N</given-names></name><name><surname>Ausiello</surname><given-names>JC</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name><name><surname>Freedberg</surname><given-names>DE</given-names></name><name><surname>Baldwin</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>CK</given-names></name><name><surname>Elkind</surname><given-names>MSV</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Bilezikian</surname><given-names>JP</given-names></name><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Wan</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Post-Acute COVID-19 syndrome</article-title><source>Nature Medicine</source><volume>27</volume><fpage>601</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01283-z</pub-id><pub-id pub-id-type="pmid">33753937</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrilli</surname><given-names>CM</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Rajagopalan</surname><given-names>H</given-names></name><name><surname>O’Donnell</surname><given-names>L</given-names></name><name><surname>Chernyak</surname><given-names>Y</given-names></name><name><surname>Tobin</surname><given-names>KA</given-names></name><name><surname>Cerfolio</surname><given-names>RJ</given-names></name><name><surname>Francois</surname><given-names>F</given-names></name><name><surname>Horwitz</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in new york city: prospective cohort study</article-title><source>BMJ</source><volume>369</volume><elocation-id>m1966</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m1966</pub-id><pub-id pub-id-type="pmid">32444366</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenforde</surname><given-names>MW</given-names></name><name><surname>Billig Rose</surname><given-names>E</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Shapiro</surname><given-names>NI</given-names></name><name><surname>Files</surname><given-names>DC</given-names></name><name><surname>Gibbs</surname><given-names>KW</given-names></name><name><surname>Prekker</surname><given-names>ME</given-names></name><name><surname>Steingrub</surname><given-names>JS</given-names></name><name><surname>Smithline</surname><given-names>HA</given-names></name><name><surname>Gong</surname><given-names>MN</given-names></name><name><surname>Aboodi</surname><given-names>MS</given-names></name><name><surname>Exline</surname><given-names>MC</given-names></name><name><surname>Henning</surname><given-names>DJ</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Qadir</surname><given-names>N</given-names></name><name><surname>Stubblefield</surname><given-names>WB</given-names></name><name><surname>Patel</surname><given-names>MM</given-names></name><name><surname>Self</surname><given-names>WH</given-names></name><name><surname>Feldstein</surname><given-names>LR</given-names></name><collab>CDC COVID-19 Response Team</collab></person-group><year iso-8601-date="2020">2020a</year><article-title>Characteristics of adult outpatients and inpatients with COVID-19-11 academic medical centers, united states, march-may 2020</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>69</volume><fpage>841</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6926e3</pub-id><pub-id pub-id-type="pmid">32614810</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenforde</surname><given-names>MW</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Billig Rose</surname><given-names>E</given-names></name><name><surname>Shapiro</surname><given-names>NI</given-names></name><name><surname>Files</surname><given-names>DC</given-names></name><name><surname>Gibbs</surname><given-names>KW</given-names></name><name><surname>Erickson</surname><given-names>HL</given-names></name><name><surname>Steingrub</surname><given-names>JS</given-names></name><name><surname>Smithline</surname><given-names>HA</given-names></name><name><surname>Gong</surname><given-names>MN</given-names></name><name><surname>Aboodi</surname><given-names>MS</given-names></name><name><surname>Exline</surname><given-names>MC</given-names></name><name><surname>Henning</surname><given-names>DJ</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Qadir</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>SM</given-names></name><name><surname>Peltan</surname><given-names>ID</given-names></name><name><surname>Rice</surname><given-names>TW</given-names></name><name><surname>Hager</surname><given-names>DN</given-names></name><name><surname>Ginde</surname><given-names>AA</given-names></name><name><surname>Stubblefield</surname><given-names>WB</given-names></name><name><surname>Patel</surname><given-names>MM</given-names></name><name><surname>Self</surname><given-names>WH</given-names></name><name><surname>Feldstein</surname><given-names>LR</given-names></name><collab>IVY Network Investigators</collab><collab>CDC COVID-19 Response Team</collab><collab>IVY Network Investigators</collab></person-group><year iso-8601-date="2020">2020b</year><article-title>Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-united states, march-june 2020</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>69</volume><fpage>993</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6930e1</pub-id><pub-id pub-id-type="pmid">32730238</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viveiros</surname><given-names>A</given-names></name><name><surname>Rasmuson</surname><given-names>J</given-names></name><name><surname>Vu</surname><given-names>J</given-names></name><name><surname>Mulvagh</surname><given-names>SL</given-names></name><name><surname>Yip</surname><given-names>CYY</given-names></name><name><surname>Norris</surname><given-names>CM</given-names></name><name><surname>Oudit</surname><given-names>GY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>320</volume><fpage>H296</fpage><lpage>H304</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00755.2020</pub-id><pub-id pub-id-type="pmid">33275517</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention</article-title><source>JAMA</source><volume>323</volume><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id><pub-id pub-id-type="pmid">32091533</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.09.023</pub-id><pub-id pub-id-type="pmid">32979574</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, china: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81182.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>DaVita Labs</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.13.22277579" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.13.22277579"/></front-stub><body><p>The authors provide valuable results from an observational study of 312 cancer patients to assess post-acute sequelae of SARS-CoV-2 infection (PASC). Although primarily descriptive and based on a relatively small sample, the study represents a solid expansion of the existing knowledge on persistent symptoms among cancer patients. The work will be of interest to oncologists working on long COVID.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81182.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>DaVita Labs</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Hajjaji</surname><given-names>Nawale</given-names></name><role>Reviewer</role><aff><institution>Oscar Lambret Cancer Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.13.22277579">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.07.13.22277579v1.full">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over Long Time Period&quot; for consideration by <italic>eLife</italic>. The evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Nawale Hajjaji.</p><p>As is customary in <italic>eLife</italic>, the reviewers have discussed their critiques with one another. What follows below is the Reviewing Editor's edited compilation of the essential and ancillary points provided by reviewers in their critiques and in their interaction post-review. Please submit a revised version that addresses these concerns directly. Although we expect that you will address these comments in your response letter, we also need to see the corresponding revision clearly marked in the text of the manuscript. Some of the reviewers' comments may seem to be simple queries or challenges that do not prompt revisions to the text. Please keep in mind, however, that readers may have the same perspective as the reviewers. Therefore, it is essential that you attempt to amend or expand the text to clarify the narrative accordingly.</p><p>Essential revisions:</p><p>Overall this was a good manuscript that could be improved by kindly addressing the concerns of the reviewer below.</p><p>The following comments could be helpful to strengthen the work:</p><p>1) Whether cancer stage or the type of anticancer therapy are associated to PASC is of great interest; these data should be within reach and added to Table 1.</p><p>2) Some patients might have participated in a vaccination trial with mRNA vaccine between March and September 2020. If this is the case, this information should be added to Table 1.</p><p>3) As mentioned by the authors in the introduction section line 94 &quot;there is limited data available on PASC in cancer patients and how it affects their cancer progression, care and treatment&quot;. The addition of these analyses would greatly strengthen the article.</p><p>4) It could be interesting to distinguish severe and mild covid at diagnosis to compare their pattern of long covid. In fact, the frequency of long covid reported in cancer patients with mild covid was only 22% (doi: 10.3389/fonc.2022.901426), much less than the frequency reported in this article.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81182.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>The following comments could be helpful to strengthen the work:</p><p>1) Whether cancer stage or the type of anticancer therapy are associated to PASC is of great interest; these data should be within reach and added to Table 1.</p></disp-quote><p>The type of underlying malignancy (hematological vs solid tumor) as well as those with metastatic diseases were similar in both PASC and non-PASC groups. However, patients with PASC were significantly less likely to have refractory or relapse diseases (19% vs 29%) Added to the Results section. High risk patients with baseline relapsing and refractory malignancy tend to be associated with more acute severe COVID and higher mortality but less long term COVID. Added to the Discussion section.</p><disp-quote content-type="editor-comment"><p>2) Some patients might have participated in a vaccination trial with mRNA vaccine between March and September 2020. If this is the case, this information should be added to Table 1.</p></disp-quote><p>None of our patients were vaccinated between March and September 2020 (added in methods).</p><disp-quote content-type="editor-comment"><p>3) As mentioned by the authors in the introduction section line 94 &quot;there is limited data available on PASC in cancer patients and how it affects their cancer progression, care and treatment&quot;. The addition of these analyses would greatly strengthen the article.</p></disp-quote><p>We thank the reviewer for their comments. We extracted additional data and found that the rates of delay in cancer treatment after COVID were similar in both PASC and non-PASC patients (43% vs 38%; p=0.44). Mortality beyond 30 days of initial COVID diagnosis was significantly higher in patients without PASC compared to those with PASC (27% vs 10%; p&lt;0.0001). Added in the results and Discussion section We have added the name of an author (Patrick Chaftari) who helped collect the additional data.</p><disp-quote content-type="editor-comment"><p>4) It could be interesting to distinguish severe and mild covid at diagnosis to compare their pattern of long covid. In fact, the frequency of long covid reported in cancer patients with mild covid was only 22% (doi: 10.3389/fonc.2022.901426), much less than the frequency reported in this article.</p></disp-quote><p>We thank the reviewers for their interesting comments. Patients without long COVID were more likely to have more acute severe COVID at diagnosis than patients who developed long COVID (26% vs 14%; p=0.009). Added in results and Discussion section.</p></body></sub-article></article>